BCR and chronic myelogenous leukemia, BCR-ABL1 positive: At CML diagnosis, the BCR-ABL1 clone dominated (with the UBA1 allele burden falling), but after tyrosine kinase inhibitor therapy suppressed CML, the UBA1-mutant clone re-expanded and the inflammatory symptoms of VEXAS recrudesced (48).